INmune Bio Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, INmune Bio stock has a consensus rating of "Strong Buy" and an average price target of $7.00. The average 1-year stock price forecast is 382.76% higher than the current stock price, while the lowest is $4.00 (+175.86%) and the highest is $9.00 (+520.69%).

Price Target: $7.00 (+382.76%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$4.00	$7.00	$7.50	$9.00
Change	+175.86%	+382.76%	+417.24%	+520.69%

Analyst Ratings

The average analyst rating for INmune Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	2	2	3	3	3	3
Buy	1	1	1	1	1	1
Hold	1	1	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	4	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason McCarthy Maxim Group	Maxim Group	Buy Maintains $8	Buy	Maintains	$8	+451.72%	Jun 3, 2026
James Molloy Alliance Global Partners	Alliance Global Partners	Buy Maintains $7	Buy	Maintains	$7	+382.76%	Apr 6, 2026
Elemer Piros Lucid Capital	Lucid Capital	Buy Upgrades $2 → $9	Buy	Upgrades	$2 → $9	+520.69%	Mar 11, 2026

Financial Forecast

Revenue This Year

n/a

from 50.00K

-100.00%

from 50.00K

Revenue Next Year

6.36M

EPS This Year

-0.60

from -1.19

EPS Next Year

-0.53

from -0.60

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	181.00K	374.00K	155.00K	14.00K	50.00K	-
Revenue Growth	1,545.46%	106.63%	-58.56%	-90.97%	257.14%	-100.00%
Gross Profit	181.00K	374.00K	155.00K	14.00K	50.00K	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	80.00%
Operating Income	-29.15M	-25.95M	-29.74M	-42.64M	-30.87M	-25.46M
Net Income	-30.34M	-27.30M	-30.01M	-42.08M	-45.93M	-24.99M
EPS	-	-	-	-	-1.19	-0.60
Free Cash Flow	-16.53M	-13.27M	-1.40M	-18.45M	-13.03M	-36.80M
No. Analysts	-	-	-	-	-	4

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	-100.0%
Avg	-100.0%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-0.44
Avg	-0.60
Low	-0.82

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-